DLG4 and Charlevoix-Saguenay spastic ataxia: Jin et al. proposed using neuroprotectors such as exenatide, a postsynaptic density protein 95 inhibitor that counteracts oxidative stress, in patients at high risk of SACS undergoing surgical procedures that predispose patients to an increased risk.